Literature DB >> 281566

Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice.

N R Lynch, J C Salomon.   

Abstract

Indomethacin was continuously administered in the drinking water of inbred C3H mice given grafts of syngeneic 3-methylcholanthrene-induced fibrosarcomas. A minor proportion of these animals died at the same time as the untreated controls, and others completely rejected their tumors; however, in most cases, the tumor growth rate was significantly slowed, and growth recommenced rapidly after drug withdrawal. This was the pattern for tumors either in their 10th to 14th transplant generation or only their third in vivo passage. Indomethacin exerted little prophylactic effect, in that it neither increased the minimal cell number required to initiate tumor growth nor significantly decreased the proportion of tumors established in drug-treated animals recieving tumor grafts. The injection of killed Corynebacterium parvum organisms into small, growing McC3-I tumors [intratumor (IT) route] caused the regression of most of these. In contrast, IT injection of BCG, ip injection of C. parvum, or IT injection of C. parvum into larger tumors had no effect. Oral administration of indomethacin enhanced BCG treatment and augmented the activity of C. parvum injected either systemically into animals with small tumors or IT into those with substantial tumor burdens. The duration of these effects was, however, often dependent on the continued administration of the drug.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 281566

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Influence of zymosan (a non-specific macrophage stimulator) and of indomethacin on liver tumours--an experimental study in rats.

Authors:  S B Holmberg; P L Naredi; G O Lindnér; I H Karlberg; P L Daneryd; L M Karlsson; A Pettersson; U Stenram; L R Hafström
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  A high level of prostaglandin E2 (PGE2) in the portal vein suppresses liver-associated immunity and promotes liver metastases.

Authors:  K Okuno; H Jinnai; Y S Lee; K Nakamura; T Hirohata; H Shigeoka; M Yasutomi
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 4.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

5.  Role of natural prostaglandins in the control of murine mammary tumor virus expression.

Authors:  J Svec; P Svec; L Halcak; V Thurzo
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

6.  Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.

Authors:  M Sato; T Narisawa; M Sano; T Takahashi; A Goto
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  The effects of indomethacin and interleukin-2 on the proliferation of lymphocytes from patients with lung cancer.

Authors:  R D Maca; J G Burford; R T Taylor
Journal:  J Clin Immunol       Date:  1985-05       Impact factor: 8.317

8.  Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.

Authors:  J L Murray; G M Kollmorgen
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

9.  The effect of indomethacin on the activation and effector function of suppressor cells from tumor-bearing mice.

Authors:  B L Pope
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Prostaglandin E2 depresses natural cytotoxicity by inhibiting interleukin-1 production by large granular lymphocytes.

Authors:  J Herman; A R Rabson
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.